NLS Pharmaceutics Eulerpool News

NLS Pharmaceutics Aktie News

NLS Pharmaceutics wird von vielen Journalisten und Investoren weltweit beobachtet. Die aktuellsten NLS Pharmaceutics News stellen wir hier zusammen.

• 21. Mai ·

  Yahoo
  NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
• 10. Februar ·

  Yahoo
  NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
• 30. Januar ·

  Yahoo
  NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
• 8. Januar ·

  Yahoo
  NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
• 30. Dezember ·

  Yahoo
  NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
• 19. Dezember ·

  Yahoo
  NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
• 12. Dezember ·

  Yahoo
  NLS Pharmaceutics expects to close Kadimastem merger by end of January
• 3. Dezember ·

  Yahoo
  NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
• 18. November ·

  Yahoo
  NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
• 5. November ·

  Yahoo
  NLS and Kadimastem stocks soar following merger agreement